- Home
- GTEC vs CRIS Comparison
GTEC vs CRIS Comparison
Compare GTEC & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | CRIS |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 14.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | GTEC | CRIS |
|---|---|---|
| Price | $0.64 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 335.9K | 122.3K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | $11,650,000.00 |
| Revenue This Year | $5.64 | $6.13 |
| Revenue Next Year | $3.93 | $7.86 |
| P/E Ratio | $0.67 | ★ N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $0.59 | $0.96 |
| 52 Week High | $2.92 | $4.50 |
Technical Indicators
Market Signals| Indicator | GTEC | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 26.21 | 32.31 |
| Support Level | $0.95 | $0.96 |
| Resistance Level | $1.15 | $1.14 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 12.11 | 10.58 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.